Tenaya CMO sells 2,877 shares at $1.33 to cover taxes

Tenaya Therapeutics, Inc. reported an insider transaction by its Chief Medical Officer.

Rhea-AI Filing Summary

Tenaya Therapeutics, Inc. reported an insider transaction by its Chief Medical Officer. On 11/17/2025, the officer sold 2,877 shares of Tenaya common stock at $1.33 per share. The sale was made to cover tax withholding obligations related to the vesting of restricted stock units that were originally granted on January 24, 2025.

After this transaction, the officer beneficially owned 169,926 shares of Tenaya common stock, including 85,838 shares that will be issued upon the vesting of restricted stock units. The filing is a routine Form 4 disclosure of insider equity activity.

Insider Trade Summary

Net Seller: 2,877 shares

Net Sell 1 txn

Insider Tingley Whittemore

Role Chief Medical Officer

Sold 2,877 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,877	$1.33	$4K

Holdings After Transaction: Common Stock — 169,926 shares (Direct)

Footnotes (2)

1. F1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.
2. F2. Includes 85,838 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tenaya Therapeutics (TNYA) disclose in this Form 4?

The filing reports that the Chief Medical Officer of Tenaya Therapeutics, Inc. sold 2,877 shares of common stock on 11/17/2025 at a price of $1.33 per share.

Why did the Tenaya Therapeutics (TNYA) officer sell 2,877 shares?

The 2,877 shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units awarded on January 24, 2025.

How many Tenaya Therapeutics (TNYA) shares does the officer own after this transaction?

Following the transaction, the officer beneficially owned 169,926 shares of Tenaya common stock, held in direct ownership.

How many Tenaya Therapeutics (TNYA) shares are tied to unvested restricted stock units?

The reported holdings include 85,838 shares of Tenaya common stock that will be issued to the officer upon the vesting of restricted stock units.

What is the reporting person’s role at Tenaya Therapeutics (TNYA)?

The reporting person is an officer of Tenaya Therapeutics, Inc., serving as the company’s Chief Medical Officer.

Is this Tenaya Therapeutics (TNYA) Form 4 filed for one or multiple insiders?

The Form 4 is filed by one reporting person, not by a group of multiple reporting persons.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/17/2025 - 08:34 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tingley Whittemore

(Last) (First) (Middle)

C/O TENAYA THERAPEUTICS, INC.

171 OYSTER POINT BLVD., 5TH FLOOR

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tenaya Therapeutics, Inc. [ TNYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S(1)		2,877	D	$1.33	169,926(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold to cover tax withholding obligations in connection with the vesting of restricted stock units awarded on January 24, 2025.

2. Includes 85,838 shares of Tenaya Therapeutics, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.

	/s/ Jennifer Drimmer Rokovich, Attorney-in-Fact	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.